J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B

J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Gwendolyn Wu · 2026-06-08

The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

Source: BioPharma Dive